Discovery and development of LX7101, a dual LIM-kinase and ROCK inhibitor for the treatment of glaucoma

ACS Medicinal Chemistry Letters

Volumn 6, Issue 1, 2015, Pages 84-88

  Harrison, Bryce A ^a,b   Almstead, Zheng Y ^a   Burgoon, Hugh ^a   Gardyan, Michael ^a   Goodwin, Nicole C ^a   Healy, Jason ^a   Liu, Ying ^a   Mabon, Ross ^a   Marinelli, Brett ^a   Samala, Lakshman ^a   Zhang, Yulian ^a   Stouch, Terry R ^a   Whitlock, N Andrew ^a   Gopinathan, Suma ^a   McKnight, Beth ^a   Wang, Shuli ^a   Patel, Nita ^a   Wilson, Alan G E ^a   Hamman, Brian D ^a   Rice, Dennis S ^a   Rawlins, David B ^a   more..

^a LEXICON PHARMACEUTICALS INC   (United States)

^b FORUM Pharmaceuticals   (United States)

Author keywords

glaucoma; kinase; LIM kinase; LX7101; ROCK inhibitor

Indexed keywords

LATANOPROST; LX 7101; PROTEIN SERINE THREONINE KINASE INHIBITOR; TIMOLOL; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; BINDING ASSAY; CROSS REACTION; DRUG CONFORMATION; DRUG DECOMPOSITION; DRUG DEGRADATION; DRUG EFFICACY; DRUG PURITY; DRUG SAFETY; DRUG SELECTIVITY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; GLAUCOMA; IC50; IN VITRO STUDY; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; METHANOLYSIS; MOUSE; NONHUMAN; NUCLEOPHILICITY; PH; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RAT; REDUCTION; SOLVOLYSIS; STEREOSPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84920737997     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml500367g     Document Type: Article

References (20)

1. Bernard, O. Lim Kinases, Regulators of Actin Dynamics. Int. J. Biochem. Cell Biol. 2007, 39, 1071-1076.
2. Manetti, F. LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Med. Res. Rev. 2012, 32, 968-998.
3. Slee, J. B.; Lowe-Krentz, L. J. Actin realignment and cofilin regulation are essential for barrier integrity during shear stress. J. Cell. Biochem. 2013, 114, 782-795.
4. Dong, Q.; Ji, Y.-S.; Cai, C.; Chen, Z.-Y. LIM Kinase 1 (LIMK1) interacts with tropomyosin-related kinase B (TrkB) and mediates brain-derived neurotrophic factor (BDNF)-induced axonal elongation. J. Biol. Chem. 2012, 287, 41720-41731.
5. Chen, Q.; Jiao, D.; Hu, H.; Song, J.; Yan, J.; Wu, L.; Xu, L.-Q. Downregulation of LIMK1 level inhibits migration of lung cancer cells and enhances sensitivity to chemotherapy drugs. Oncol. Res. 2013, 20, 491-498.
6. Gamell, C.; Schofield, A. V.; Suryadinata, R.; Sarcevic, B.; Bernard, O. LIMK2 mediates resistance to chemotherapeutic drugs in neuroblastoma cells through regulation of drug-induced cell cycle arrest. PLoS One 2013, 8, e72850.
7. Manetti, F. HIV-1 proteins join the family of LIM kinase partners. New roads open up for HIV-1 treatment. Drug Discovery Today 2012, 17, 81-88.
8. Olson, M. F. Follow the leader: LIM kinases pave the way for collective tumor cell invasion. Cell Cycle 2010, 9, 4417-4418.
9. He, L.; Seitz, S. P.; Trainor, G. L.; Tortolani, D.; Vaccaro, W.; Poss, M.; Tarby, C. M.; Tokarski, J. S.; Penhallow, B.; Hung, C.-Y.; Attar, R.; Lin, T.-A. Modulation of cofilin phosphorylation by inhibition of the Lim family kinases. Bioorg. Med. Chem. Lett. 2012, 22, 5995-5998.
10. Sleebs, B. E.; Nikolakopoulos, G.; Street, I. P.; Falk, H.; Baell, J. B. Identification of 5,6-substituted 4-aminothieno[2,3-d]pyrimidines as LIMK1 inhibitors. Bioorg. Med. Chem. Lett. 2011, 21, 5992-5994.
11. Ross-Macdonald, P.; de Silva, H.; Guo, Q.; Xiao, H.; Hung, C.-Y.; Penhallow, B.; Markwalder, J.; He, L.; Attar, R. M.; Lin, T.; Seitz, S.; Tilford, C.; Wardwell-Swanson, J.; Jackson, D. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol. Cancer Ther. 2008, 7, 3490-3498.
12. Harrison, B. A.; Whitlock, N. A.; Voronkov, M. V.; Almstead, Z. Y.; Gu, K.-J.; Mabon, R.; Gardyan, M.; Hamman, B. D.; Allen, J.; Gopinathan, S.; McKnight, B.; Crist, M.; Zhang, Y.; Liu, Y.; Courtney, L. F.; Key, B.; Zhou, J.; Patel, N.; Yates, P. W.; Liu, Q.; Wilson, A. G. E.; Kimball, S. D.; Crosson, C. E.; Rice, D. S.; Rawlins, D. B. Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma. J. Med. Chem. 2009, 52, 6515-6518.
13. Whitlock, N. A.; McKnight, B.; Corcoran, K. N.; Rodriguez, L. A.; Rice, D. S. Increased intraocular pressure in mice treated with dexamethasone. Invest. Ophthalmol. Vis. Sci. 2010, 51, 6496-6503.
14. Quigley, H. A. Glaucoma. Lancet 2011, 377, 1367-1377.
15. Bettin, P.; Di Matteo, F. Glaucoma: present challenges and future trends. Ophthalmic Res. 2013, 50, 197-208.
16. Toris, C. B.; Koepsell, S. A.; Yablonski, M. E.; Camras, C. B. Aqueous humor dynamics in ocular hypertensive patients. J. Glaucoma 2002, 11, 253-258.
17. Wang, S. K.; Chang, R. T. An emerging treatment option for glaucoma: Rho kinase inhibitors. Clin. Ophthalmol. 2014, 8, 883-890.
18. Food Drug Administration Center for Drugs Evaluation Research (2014). Guidance for Industry: ANDAs: Stability Testing of Drug Substances and Products. Questions and Answers (FDA Maryland).
19. The modeling was done with the CFF98 Force Field within the Discover and Insight programs (Biovia, Inc. (previously Accelrys, Inc.), San Diego, CA) and confirmed with ICM (Molsoft, LLC, San Diego, CA) employing the MMFF force field.
20. Goodwin, N. C.; Cianchetta, G.; Burgoon, H. A.; Healy, J.; Mabon, R.; Strobel, E. D.; Allen, J.; Wang, S.; Hamman, B. D.; Rawlins, D. B. Discovery of a type III inhibitor of LIM kinase 2 that binds in a DFG-out conformation. ACS Med. Chem. Lett. 2014, DOI: 10.1021/ml500242y.